Curated News
By: NewsRamp Editorial Staff
July 10, 2026

Greenland Mines Secures Australian Patent for Klotho Gene Therapy

Discuss on LinkedIn Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Greenland Mines secures Australian patent for Klotho gene therapy, strengthening its IP moat in neuromuscular disease treatments.
  • Australian patent covers gene therapy constructs, stem cells, and delivery systems for expressing human Klotho protein to treat ALS.
  • This gene therapy patent advances potential treatments for ALS and neuromuscular diseases, offering hope for patients worldwide.
  • Klotho protein, known as the 'longevity gene,' may now be used in gene therapy to combat muscle-wasting diseases.

Impact - Why it Matters

This patent grant strengthens Greenland Mines' intellectual property in gene therapy for neuromuscular diseases, including ALS, potentially accelerating development of treatments for conditions with high unmet need. For investors, it solidifies the company's biotech division value and may attract partnership or licensing interest, while for patients, it offers hope for novel therapies targeting fatal disorders like ALS.

Summary

Greenland Mines Ltd (NASDAQ: GRML) has announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division. This patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform, with claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The company is a Nasdaq-listed firm with two operating divisions: Mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project; and Biotech, including Klotho’s KLTO-202 primary indication for ALS. Its strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.

To view the full press release, visit: https://nnw.fm/PVbbH

NetworkNewsWire (NNW) is a specialized communications platform focusing on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team, NNW is uniquely positioned to serve companies wanting to reach a wide audience of investors, influencers, consumers, journalists and the general public. NNW brings its clients unparalleled recognition and brand awareness, cutting through information overload in today’s market.

For more information, please visit https://www.NetworkNewsWire.com. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Greenland Mines Secures Australian Patent for Klotho Gene Therapy

blockchain registration record for this content.